HCP 1302

Drug Profile

HCP 1302

Alternative Names: HCP1302

Latest Information Update: 16 Mar 2016

Price : $50

At a glance

  • Originator Hanmi Pharmaceutical
  • Class Erectile dysfunction therapies; Small interfering RNA
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Erectile dysfunction; Hypertension

Most Recent Events

  • 31 Dec 2015 Preregistration for Hypertension in South Korea (unspecified route)
  • 31 Dec 2015 Preregistration for Erectile dysfunction in South Korea (unspecified route)
  • 01 Sep 2015 Phase-III clinical trials in Erectile dysfunction in South Korea (unspecified route) (NCT02587988)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top